Replies to post #22639 on Cytodyn Inc (CYDY)

[finesand]

now we may debate differences of CD01 + ext to CD02 and CD03.

They claimed they used 350mg in CD01, which is being used in CD02 Combo and the low dosage arm of CD03 Mono.

Selection of patients in CD01 surely makes a difference.

May elaborate over long weekend, shall we?

- CD02 Pivotal Combo Phase 3, 52 patients for 25 weeks, up until September 2018
-- ClinicalTrials.gov Identifier: NCT02483078

- CD03 Mono Phase 3, 300 patients for 48 weeks
-- ClinicalTrials.gov Identifier: NCT02859961

- CD01 Phase 2b, 40 patients for 12 week monotherapy
-- ClinicalTrials.gov Identifier: ?????

- CD01 Long Term Extension Study
-- ClinicalTrials.gov Identifier: ?????

Can we add the ClinicalTrials.gov Identifier to CD01+?

Complete overview https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140999067

[BlackDoggie]

Good catch, I admittedly never saw that in your previous post. I dare say that most here did not know of the existence of that paper, but I could be wrong on that. It hasn't been broadly discussed, that's for sure. I've tended to skim most of your posts because overall I agree with you, and the valuation exercises - while thoroughly supported and I tend to generally agree with them - don't hold much interest for me. I know what I think it's worth, and I think I'm in good shape anywhere within a wide variance of what I believe it's worth! All of that said, I do still appreciate your contributions to the board.

On another note, I wouldn't be quick to believe that those phone calls are anything other than a concerted attempt to gather the votes necessary to pass the increase in A/S. I've seen the same phone calls, with similar knowledge of exact share counts, etc, with other tickers with shareholder votes approaching. The calls are most likely genuine. I'd love to be wrong, but I don't see evidence of anything else at this point.